Literature DB >> 22236048

Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.

J de Vos1, S Ramos Vega, E Noorman, P de Vos.   

Abstract

In human medicine, primary frontal sinus squamous cell carcinoma (pFS-SCC) is not frequently reported. In veterinary medicine, frontal sinus SCC is exclusively described as an extension of nasal cavity SCC. To our knowledge, this is the first publication concerning canine pFS-SCC, diagnosed using histology or cytology and medical imaging, in three dogs. The tumours extended into the orbit or brain cavity, without nasal involvement. Treatment was initiated with piroxicam-carboplatin. Prolongation of carboplatin delivery with a low dose intensity was performed on dogs with a favourable initial response. Dog 1 achieved a complete remission (CR), but was euthanized 344 days after start of therapy. Dog 2, still alive 3 years after start of therapy and in CR, received 14 carboplatin deliveries. In dog 3, after changing the treatment protocol into piroxicam-toceranib, a significant tumour reduction occurred, but the dog was euthanized after 195 days because of a relapse.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22236048     DOI: 10.1111/j.1476-5829.2011.00292.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  3 in total

1.  Primary frontal sinus squamous cell carcinoma in a dog treated with surgical excision.

Authors:  Janet A Grimes; Candace J Pagano; Bonnie B Boudreaux
Journal:  Can Vet J       Date:  2017-01       Impact factor: 1.008

2.  Superior orbitectomy and chemotherapy in a dog with frontal sinus squamous cell carcinoma: a case report and review of the literature.

Authors:  Andrea Steinmetz
Journal:  Clin Case Rep       Date:  2017-03-08

3.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

Authors:  Milan Milovancev; Stuart C Helfand; Kevin Marley; Cheri P Goodall; Christiane V Löhr; Shay Bracha
Journal:  BMC Vet Res       Date:  2016-06-04       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.